Sobi and Innate partnership becomes effective after closing conditions
Sobi and Innate Pharma said their previously announced strategic partnership is now effective following completion of closing conditions.
Story updates
03:30:43 AM UTC
SquawkNews
Sobi said its strategic partnership with Innate Pharma is now effective, triggering a $75M payment. The deal backs the TELLOMAK-3 Phase 3 CTCL program and gives Sobi exclusive global rights to commercialise lacutamab upon potential accelerated approval.Material DetailsContext by AI AnalystThis form…
Sobi said its strategic partnership with Innate Pharma is now effective after closing conditions were met, triggering a $75M payment. The agreement supports the TELLOMAK-3 Phase 3 CTCL program and gives Sobi exclusive global rights to commercialise lacutamab upon potential accelerated approval.